BRIEF-Sarepta Therapeutics Provides FY 2018 Rev Forecast For Exondys 51
January 08, 2018 at 13:49 PM EST
* SAREPTA THERAPEUTICS PRE-ANNOUNCES FOURTH QUARTER 2017 REVENUE AND PROVIDES FULL-YEAR 2018 REVENUE GUIDANCE FOR EXONDYS 51® (ETEPLIRSEN), REPRESENTING APPROXIMATELY 100 PERCENT YEAR-OVER-YEAR GROWTH
